Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at the Cantor 2026 Global Healthcare Conference, scheduled for September 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on September 10 from 3:55 to 4:25 p.m. ET. A live webcast and replay will be available through the Investors section of the Tonix website. This participation underscores Tonix's commitment to engaging with the investment community and highlighting its recent corporate and clinical developments.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on developing treatments for central nervous system (CNS) and immunology conditions with high unmet medical needs. The company's flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), recently received approval and represents the first new treatment for fibromyalgia in over 15 years. This approval marks a significant milestone, offering a novel therapeutic option for patients suffering from this chronic pain condition. Tonix's CNS commercial infrastructure also supports its marketed products for acute migraine, including Zembrace® SymTouch® and Tosymra®.
Beyond its commercial portfolio, Tonix is advancing a robust pipeline. The company is currently conducting Phase 2 clinical trials to evaluate TONMYA's potential in major depressive disorder and acute stress disorder, which could expand its indications and address other psychiatric conditions. Additionally, the CNS pipeline includes TNX-2900, a Phase 2-ready candidate for the treatment of Prader-Willi syndrome, a rare genetic disorder. On the immunology front, Tonix is developing monoclonal antibodies, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. These programs highlight the company's strategic focus on areas where existing therapies are limited.
The presentation at the Cantor conference is expected to provide investors with insights into Tonix's commercial progress and clinical milestones. The company's participation in such events is part of its broader investor relations strategy to communicate its value proposition. For those unable to attend, the webcast and replay will ensure accessibility to the company's updates.
It is important to note that Tonix's product development candidates are investigational drugs or biologics; their efficacy and safety have not been established, and they have not been approved for any indication. Investors and stakeholders are encouraged to review the full press release for more details via [NetworkNewsWire's coverage](https://nnw.fm/hajiz).
Tonix Pharmaceuticals' presence at this prominent healthcare conference underscores its dedication to advancing treatments in CNS and immunology, with the potential to significantly impact patient care and the biotechnology industry. The company's continued progress in clinical trials and commercial launches positions it as a key player in addressing unmet medical needs.
